Sevelamer and Secondary Hyperparathyroidism in Chronic Kidney Disease
| Status: | Completed |
|---|---|
| Conditions: | Renal Impairment / Chronic Kidney Disease, Endocrine |
| Therapuetic Areas: | Endocrinology, Nephrology / Urology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 5/27/2013 |
| Start Date: | April 2010 |
| End Date: | August 2012 |
| Contact: | Kenneth R. Phelps, M.D. |
| Email: | kenneth.phelps@va.gov |
| Phone: | 518-626-6415 |
The Effect of Sevelamer Carbonate on Critical Variables in the Pathogenesis of Secondary Hyperparathyroidism
The hypothesis underlying this study is that phosphate interferes with PTH-mediated calcium
reabsorption in the distal nephron and thereby necessitates supranormal [PTH]to maintain
normocalcemia in chronic kidney disease. This study will examine the hypothesis with
measures of phosphate homeostasis and calcium reabsorption. A double-blind trial of the
intestinal phosphate binder sevelamer carbonate will be employed to examine whether
reductions in phosphate influx alter distal nephron phosphate concentration and the [PTH]
required for calcium reabsorption in the expected manner.
Inclusion Criteria:
- eGFR < 60 ml/min
- age at least 18 years
Exclusion Criteria:
- any primary parathyroid disease
We found this trial at
1
site
Click here to add this to my saved trials
